BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 24649961)

  • 1. Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim YI; Park JW; Kwak HW; Kim BH; Lee JH; Lee IJ; Kim TH; Kim SH; Koh YH; Kim HB; Kim CM
    Liver Int; 2014 Sep; 34(8):1278-86. PubMed ID: 24649961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
    Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases.
    Yoo JJ; Lee JH; Lee SH; Lee M; Lee DH; Cho Y; Lee YB; Yu SJ; Kim HC; Kim YJ; Yoon JH; Kim CY; Lee HS
    PLoS One; 2014; 9(11):e113926. PubMed ID: 25427152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
    Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
    Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
    Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients.
    Song YG; Shin SW; Cho SK; Choi D; Rhim H; Lee MW; Kim YS; Park KB; Park HS; Choo SW; Do YS; Choo IW; Hyun D
    Acta Radiol; 2015 Jan; 56(1):70-7. PubMed ID: 24518688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection.
    Shim JH; Kim KM; Lee YJ; Ko GY; Yoon HK; Sung KB; Park KM; Lee SG; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    Ann Surg Oncol; 2010 Mar; 17(3):869-77. PubMed ID: 20033326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection.
    Meniconi RL; Komatsu S; Perdigao F; Boëlle PY; Soubrane O; Scatton O
    Surgery; 2015 Mar; 157(3):454-62. PubMed ID: 25633732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection.
    Eguchi S; Matsumoto S; Hamasaki K; Takatsuki M; Hidaka M; Tajima Y; Sakamoto I; Kanematsu T
    J Hepatobiliary Pancreat Surg; 2008; 15(6):627-33. PubMed ID: 18987934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study.
    Wang K; Liu G; Li J; Yan Z; Xia Y; Wan X; Ji Y; Lau WY; Wu M; Shen F
    Eur J Surg Oncol; 2015 Feb; 41(2):236-42. PubMed ID: 25434327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoembolization of recurrent hepatoma after curative resection: prognostic factors.
    Zu QQ; Liu S; Zhou CG; Yang ZQ; Xia JG; Zhao LB; Shi HB
    AJR Am J Roentgenol; 2015 Jun; 204(6):1322-8. PubMed ID: 26001244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation.
    Terzi E; Ray Kim W; Sanchez W; Charlton MR; Schmeltzer P; Gores GJ; Andrews JC; Smyrk TC; Heimbach JK
    Liver Transpl; 2015 Feb; 21(2):248-57. PubMed ID: 25371111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Jung SJ; An S; Woo SM; Kim HB; Koh YH; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1051-6. PubMed ID: 22098152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study.
    Bargellini I; Sacco R; Bozzi E; Bertini M; Ginanni B; Romano A; Cicorelli A; Tumino E; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
    Eur J Radiol; 2012 Jun; 81(6):1173-8. PubMed ID: 21466931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.